Rui Avelar
Chief Tech/Sci/R&D Officer bij EVOLUS, INC.
Vermogen: 5 M $ op 31-03-2024
Profiel
Rui Avelar is currently the Chief Medical Officer, Head-Research & Development at Evolus, Inc. He previously held the position of Chief Medical Officer at Allergan Medical Optics from 2011 to 2013 and at AEON Biopharma Sub, Inc. from 2014 to 2018.
Dr. Avelar obtained his doctorate degree from the University of Toronto in 1989.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
EVOLUS, INC.
0.61% | 19-03-2024 | 372 288 ( 0.61% ) | 5 M $ | 31-03-2024 |
Actieve functies van Rui Avelar
| Bedrijven | Functie | Begin |
|---|---|---|
| EVOLUS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2014 |
Eerdere bekende functies van Rui Avelar
| Bedrijven | Functie | Einde |
|---|---|---|
AEON Biopharma Sub, Inc.
 AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Chief Tech/Sci/R&D Officer | 01-02-2018 |
| Allergan Medical Optics | Chief Tech/Sci/R&D Officer | 01-12-2013 |
Opleiding van Rui Avelar
| University of Toronto | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| EVOLUS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Allergan Medical Optics | |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Health Technology |
